Literature DB >> 7835579

Common occurrence of APC and K-ras gene mutations in the spectrum of colitis-associated neoplasias.

M S Redston1, N Papadopoulos, C Caldas, K W Kinzler, S E Kern.   

Abstract

BACKGROUND/AIMS: Chronic colitis is associated with an increased risk of colorectal neoplasia, creating a need for early diagnosis in this population. Little is yet known of the genetic changes of early lesions. Cases of colitis-associated neoplasia were analyzed for APC and K-ras mutations with special emphasis given to the spectrum of noninvasive lesions.
METHODS: Ten patients were studied. APC mutations were screened by an in vitro synthesized protein assay, and K-ras mutations were screened by a ligation assay.
RESULTS: APC mutations were found in 5 patients, including dysplasias. K-ras mutations were present in 5 patients and in all classes of lesions, including 5 of 14 lesions indefinite for dysplasia. In only 2 patients were no mutations found.
CONCLUSIONS: Mutations of APC and K-ras are common in colitis-associated neoplasia and can occur early in neoplastic progression. Serrated lesions and lesions indefinite for dysplasia may harbor genetic changes and thus are clonal, highlighting the importance of distinguishing them histologically. Assays for APC and K-ras mutations are promising as adjuncts to surveillance programs. Care will be needed in their application because the confident diagnosis of early lesions presumed to be of lesser clinical importance will raise new issues concerning prudent patient management.

Entities:  

Mesh:

Year:  1995        PMID: 7835579     DOI: 10.1016/0016-5085(95)90064-0

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  35 in total

1.  Allele loss, replication errors and loss of expression of E-cadherin in colorectal cancers.

Authors:  M Ilyas; I P Tomlinson; A Hanby; I C Talbot; W F Bodmer
Journal:  Gut       Date:  1997-05       Impact factor: 23.059

2.  Bcl-2 expression in colorectal tumors: evidence of different pathways in sporadic and ulcerative-colitis-associated carcinomas.

Authors:  M Ilyas; I P Tomlinson; A M Hanby; T Yao; W F Bodmer; I C Talbot
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

Review 3.  Inflammatory bowel disease-associated colorectal cancer: proctocolectomy and mucosectomy do not necessarily eliminate pouch-related cancer incidences.

Authors:  Amosy E M'Koma; Harold L Moses; Samuel E Adunyah
Journal:  Int J Colorectal Dis       Date:  2011-02-11       Impact factor: 2.571

4.  A quantitative assay for assessing allelic proportions by iterative gap ligation.

Authors:  J Stewart; P Kozlowski; M Sowden; E Messing; H C Smith
Journal:  Nucleic Acids Res       Date:  1998-02-15       Impact factor: 16.971

5.  Combinatorial library diversity: probability assessment of library populations.

Authors:  B Ward; T Juehne
Journal:  Nucleic Acids Res       Date:  1998-02-15       Impact factor: 16.971

Review 6.  Molecular Alterations of Colorectal Cancer with Inflammatory Bowel Disease.

Authors:  Masakazu Yashiro
Journal:  Dig Dis Sci       Date:  2015-04-04       Impact factor: 3.199

7.  Survival of Colorectal Cancer in Patients With or Without Inflammatory Bowel Disease: A Meta-Analysis.

Authors:  Baochi Ou; Jingkun Zhao; Shaopei Guan; Aiguo Lu
Journal:  Dig Dis Sci       Date:  2015-10-30       Impact factor: 3.199

Review 8.  Stat3: friend or foe in colitis and colitis-associated cancer?

Authors:  Jie Han; Arianne L Theiss
Journal:  Inflamm Bowel Dis       Date:  2014-12       Impact factor: 5.325

Review 9.  What we could do now: molecular pathology of colorectal cancer.

Authors:  R S Houlston
Journal:  Mol Pathol       Date:  2001-08

Review 10.  Genomic and molecular alterations in human inflammatory bowel disease-associated colorectal cancer.

Authors:  Marie Muller; Franck Hansmannel; Djesia Arnone; Myriam Choukour; Ndeye Coumba Ndiaye; Tunay Kokten; Rémi Houlgatte; Laurent Peyrin-Biroulet
Journal:  United European Gastroenterol J       Date:  2020-04-08       Impact factor: 4.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.